Key facts
- This page summarizes LAV Biosciences Fund V, L.P.'s Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Nov 2022, 15:56.
LAV Biosciences Fund V, L.P. - 23 Nov 2022 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TERN
- Reported as of
- 23 Nov 2022
- Net transaction value
- -$8,250,000
- Reporting owner signature
- /s/ Yun Luo, as Authorized Signatory of LAV Biosciences Fund V, L.P.
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
LAV Biosciences Fund V, L.P. filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 28 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$8,250,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TERN
transaction
Common Stock
Sale
- Transaction value
- $5,500,000
- Shares
- -1,000,000
- Change %
- -71%
- Price
- $5.50
- Shares after
- 405,583
- Date
- 23 Nov 2022
- Ownership
- See footnotes
- Footnotes
- F1, F2
TERN
transaction
Common Stock
Sale
- Transaction value
- $1,833,337
- Shares
- -333,334
- Change %
- -24%
- Price
- $5.50
- Shares after
- 1,059,523
- Date
- 23 Nov 2022
- Ownership
- See footnotes
- Footnotes
- F2, F3
TERN
transaction
Common Stock
Sale
- Transaction value
- $916,663
- Shares
- -166,666
- Change %
- -24%
- Price
- $5.50
- Shares after
- 529,762
- Date
- 23 Nov 2022
- Ownership
- See footnotes
- Footnotes
- F2, F4
TERN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,286,698
- Date
- 23 Nov 2022
- Ownership
- See footnotes
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Shares held by LAV Biosciences Fund V, L.P.
Footnote F2
LAV Corporate GP, Ltd. is the general partner of LAV GP III, L.P., which is the general partner of the parent entity of Hopewell Resources Holdings Limited and Oriental Spring Venture Limited. LAV Corporate IV GP, Ltd., is the general partner of LAV GP IV, L.P., which is the general partner of the parent entity of LAV Aqua Limited. LAV Corporate V GP, Ltd., is the general partner of LAV GP V, L.P., which is the general partner of LAV Biosciences Fund V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate GP, Ltd., LAV Corporate IV GP, Ltd., and LAV Corporate V, L.P. and has all voting and investment power with respect to shares beneficially held by each of Hopewell Resources Holdings Limited, Oriental Spring Venture Limited, LAV Aqua Limited and LAV Biosciences Fund V, L.P. Dr. Yi Shi is a managing partner at Lilly Asia Ventures.
Footnote F3
Shares held by Hopewell Resources Holdings Limited.
Footnote F4
Shares held by Oriental Spring Venture Limited.
Footnote F5
Shares held by LAV Aqua Limited.